FASB on Wednesday clarified its plans regarding requirements for specific qualitative disclosures and the definition of “financial institution” that will be included in the liquidity disclosures ...
A phase II trial of sorafenib (SO) in advanced chordoma patients (pt). This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results